Monoclonal Antibodies and Immuno-PET Imaging: An Overview
Yıl: 2023 Cilt: 48 Sayı: 1 Sayfa Aralığı: 165 - 182 Metin Dili: İngilizce DOI: 10.55262/fabadeczacilik.1172020 İndeks Tarihi: 28-03-2023
Monoclonal Antibodies and Immuno-PET Imaging: An Overview
Öz: Radiopharmaceuticals are radioactive medicines used for imaging and/or therapeutic purposes, consisting of radionuclidic and pharmaceutical parts. While Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) methods are commonly used for imaging purposes, the immuno- PET imaging method has gained popularity recently. Immuno- PET imaging method is a combination of PET radionuclides and biomolecules, especially monoclonal antibodies (mAb), proteins, peptides, which are frequently used for the imaging of different types of cancer. Radionuclides with long half-lives are generally used in immuno-PET imaging. Long biological half-lives of mAbs are the most important reason to be preferred for immuno-PET imaging. Today, Zirconium-89 (Zr-89), Iodine-124 (I-124) with long half- lives and Copper-64 (Cu-64) and Yttrium-86 (Y-86) radionuclides with relatively long half-lives are preferred in immuno-PET imaging. In this article, preclinical and clinical studies of Zr-89, Cu-64, I-124 and Y-86-labeled mAbs with a long half-lives were reviewed. Also, these 4 radionuclides, which are frequently used in the labelling of biomolecules (particularly mAbs) are compared.
Anahtar Kelime: Monoklonal Antikorlar ve Immuno-PET Görüntülenmesi: Genel Bakış
Öz: Radyofarmasötikler, radyonüklidik ve farmasötik kısımlardan oluşan görüntüleme ve/veya tedavi amaçlı kullanılan radyoaktif ilaçlardır. Görüntüleme amaçlı pozitron emisyon tomografisi (PET) ve tek foton emisyon tomografisi (SPECT) yöntemleri kullanılırken, son zamanlarda immuno-PET görüntüleme yöntemi de popülerlik kazanmıştır. PET radyonüklidleri ve biyomoleküllerin, özellikle monoklonal antikor (mAb), protein, peptit kombinasyonları olan immuno-PET görüntüleme ajanları ve yöntemi özellikle farklı kanser türlerinin görüntülenmesinde sıklıkla kullanılmaktadır. İmmuno- PET görüntülenmesinde sıklıkla uzun yarılanma ömrüne sahip radyonüklidlerden yararlanılmaktadır. Bunun en önemli nedeni ise uzun biyolojik yarılanma ömrüne sahip mAb’ların immuno- PET görüntülenmesinde sıklıkla tercih edilmeleridir. Günümüzde uzun yarılanma ömrüne sahip Zirkonyum-89 (Zr-89), Iyot-124 (I-124) ve nispeten uzun yarılanma ömrüne sahip Bakır-64 (Cu- 64) ile İtriyum-86 (Y-86) radyonüklitleri tercih edilmektedir. Bu çalışmada, kullanımı ve popüleritesi giderek artan mAb’ların immuno-PET görüntülenmesinde kullanımları ve uzun yarılanma ömrüne sahip klinik ve preklinik çalışmaları süren Zr-89, Cu-64, I-124 ve Y-86 ile işaretli mAb’ların çalışmaları derlenmiştir, özellikle mAb’ların, işaretlenmesinde sıklıkla kullanılan bu 4 radyonüklidin karşılaştırılmasına yer verilmiştir.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
- (CDER), U. S. D. o. H. a. H. S. F. a. D. A. C. f. D. E. a. R. (2011). PET Drugs- Current Good Manufacturing Practice (cGMP)- Small Entity Compliance Guide. Retrieved from
- Achmad, A., Hanaoka, H., Yoshioka, H., Yamamoto, S., Tominaga, H., Araki, T., . . . Endo, K. (2012). Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emis- sion tomography. Cancer Sci, 103(3), 600-605. doi:10.1111/j.1349-7006.2011.02166.x
- Aluicio-Sarduy, E., Ellison, P. A., Barnhart, T. E., Cai, W., Nickles, R. J., & Engle, J. W. (2018). PET radio- metals for antibody labeling. J Labelled Comp Ra- diopharm, 61(9), 636-651. doi:10.1002/jlcr.3607
- Anderson, C. J., & Ferdani, R. (2009). Cooper-64 Radiopharmaceuticals for PET Imaging of Can- cer: Advances in Preclinical and Clinical Re- search. Cancer Biother Radiopharm, 24, 379-394. doi:10.1089=cbr.2009.0674
- Avila-Rodriguez, M. A., Nye, J. A., & Nickles, R. J. (2007). Simultaneous production of high specific activity 64Cu and 61Co with 11.4 MeV protons on enriched 64Ni nuclei. Appl Radiat Isot, 65(10), 1115-1120. doi:10.1016/j.apradiso.2007.05.012
- Barbaros, B., & Dikmen, M. (2015). Cancer Immuno- therapy. Erciyes University Journal of the Institute of Science and Technology, 31(4), 177-181.
- Battal, H., & Özer, A. Y. (2021). Copper-64 Radio- pharmaceuticals-An Overview. In A. Y. Özer (Ed.), New Trensd in Radiopharmaceuticals (pp. 9-15). Ankara: Türkiye Klinikleri.
- Borjesson, P. K., Jauw, Y. W., Boellaard, R., de Bree, R., Comans, E. F., Roos, J. C., . . . van Dongen, G. A. (2006). Performance of immuno-positron emis- sion tomography with zirconium-89-labeled chi- meric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res, 12(7 Pt 1), 2133-2140. doi:10.1158/1078-0432.CCR-05-2137
- Börjesson, P. K., Jauw, Y. W., de Bree, R., Roos, J. C., Castelijns, J. A., Leemans, C. R., . . . Boellaard, R. (2009). Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. Journal of Nuclear Medicine, 50(11), 1828-1836.
- Breedveld, F. C. (2000a). Therapeutic monoclonal an- tibodies. Lancet, 355(9205), 735-740. doi:10.1016/ s0140-6736(00)01034-5
- Breedveld, F. C. (2000b). Therapeutic monoclo- nal antibodies. The Lancet, 355(9205), 735-740. doi:10.1016/s0140-6736(00)01034-5
- Cai, W., Chen, K., He, L., Cao, Q., Koong, A., & Chen, X. (2007). Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal an- tibody. Eur J Nucl Med Mol Imaging, 34(6), 850- 858. doi:10.1007/s00259-006-0361-6
- Carrasquillo, J. A., O’Donoghue, J. A., Beylergil, V., Ruan, S., Pandit-Taskar, N., Larson, S. M., . . . Abou-Alfa, G. K. (2018). I-124 codrituzumab imaging and biodistribution in patients with he- patocellular carcinoma. EJNMMI Res, 8(1), 20. doi:10.1186/s13550-018-0374-8
- Carrasquillo, J. A., Pandit-Taskar, N., O’Donoghue, J. A., Humm, J. L., Zanzonico, P., Smith-Jones, P. M., . . . Larson, S. M. (2011). (124)I-huA33 antibody PET of colorectal cancer. J Nucl Med, 52(8), 1173- 1180. doi:10.2967/jnumed.110.086165
- Crisan, G., Moldovean-Cioroianu, N. S., Timaru, D. G., Andries, G., Cainap, C., & Chis, V. (2022). Ra- diopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade. Int J Mol Sci, 23(9). doi:10.3390/ijms23095023
- Cutler, C. S., Hennkens, H. M., Sisay, N., Hucli- er-Markai, S., & Jurisson, S. S. (2013). Radiomet- als for combined imaging and therapy. Chem Rev, 113(2), 858-883. doi:10.1021/cr3003104
- Dijkers, E., Hooge, M. N. L.-d., Kosterink, J. G., Jager, P. L., Brouwers, A. H., Perk, L. R., . . . Vries, E. G. d. (2007). Characterization of 89Zr-trastuzumab for clinical HER2 immunoPET imaging. Journal of Clinical Oncology, 25(18_suppl), 3508-3508. doi:10.1200/jco.2007.25.18_suppl.3508
- Dijkers, E. C., Kosterink, J. G., Rademaker, A. P., Perk, L. R., van Dongen, G. A., Bart, J., . . . Lub-de Hooge, M. N. (2009). Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med, 50(6), 974-981. doi:10.2967/jnumed.108.060392
- Dillman, R. O. (2006). Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies. Clin Exp Med, 6(1), 1-12. doi:10.1007/s10238-006-0087-6
- Dilworth, J. R., & Pascu, S. I. (2018). The chemistry of PET imaging with zirconium-89. Chem Soc Rev, 47(8), 2554-2571. doi:10.1039/c7cs00014f
- Divgi, C. R., Pandit-Taskar, N., Jungbluth, A. A., Reuter, V. E., Gönen, M., Ruan, S., . . . Russo, P. (2007). Preoperative characterisation of clear- cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol, 8(4), 304-310. doi:10.1016/s1470- 2045(07)70044-x
- Drude, N., Tienken, L., & Mottaghy, F. M. (2017). Theranostic and nanotheranostic probes in nucle- ar medicine. Methods, 130, 14-22. doi:10.1016/j. ymeth.2017.07.004
- Ecker, D. M., Jones, S. D., & Levine, H. L. (2015). The therapeutic monoclonal antibody market. MAbs, 7(1), 9-14. doi:10.4161/19420862.2015.989042
- Ferreira, C. L., Yapp, D. T., Lamsa, E., Gleave, M., Bensimon, C., Jurek, P., & Kiefer, G. E. (2008). Evaluation of novel bifunctional chelates for the development of Cu-64-based radiopharmaceuti- cals. Nucl Med Biol, 35(8), 875-882. doi:10.1016/j. nucmedbio.2008.09.001
- Gillings, N., Hjelstuen, O., Ballinger, J., Behe, M., Decristoforo, C., Elsinga, P., . . . Todde, S. (2021). Guideline on current good radiopharmacy prac- tice (cGRPP) for the small-scale preparation of ra- diopharmaceuticals. EJNMMI Radiopharm Chem, 6(1), 8. doi:10.1186/s41181-021-00123-2
- Grubmuller, B., Baum, R. P., Capasso, E., Singh, A., Ahmadi, Y., Knoll, P., . . . Mirzaei, S. (2016). (64) Cu-PSMA-617 PET/CT Imaging of Prostate Ad- enocarcinoma: First In-Human Studies. Cancer Biother Radiopharm, 31(8), 277-286. doi:10.1089/ cbr.2015.1964
- Guideline on Radiopharmaceuticals, CHMP, EMEA/ CHMP/QWP/306970/2007 (draft released for consultation). (2007). Retrieved from https:// www.gmp-compliance.org/files/guidemgr/EMA_ WC500003538_radio.pdf
- Herrero Alvarez, N., Bauer, D., Hernandez-Gil, J., & Lewis, J. S. (2021). Recent Advances in Radiomet- als for Combined Imaging and Therapy in Cancer. ChemMedChem, 16(19), 2909-2941. doi:10.1002/ cmdc.202100135
- Heskamp, S., Raave, R., Boerman, O., Rijpkema, M., Goncalves, V., & Denat, F. (2017). (89)Zr-Immu- no-Positron Emission Tomography in Oncology: State-of-the-Art (89)Zr Radiochemistry. Biocon- jug Chem, 28(9), 2211-2223. doi:10.1021/acs.bio- conjchem.7b00325
- Holland, J., Sheh, Y., Smith-Jones, P., & Lewis, J. (2009). Zr-89 radiolabeling of monoclonal anti- bodies for immunoPET. Journal of Nuclear Med- icine, 50(supplement 2), 497-497.
- Holland, J. P., Divilov, V., Bander, N. H., Smith-Jones, P. M., Larson, S. M., & Lewis, J. S. (2010). 89Zr- DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med, 51(8), 1293-1300. doi:10.2967/jnumed.110.076174
- Holland, J. P., Williamson, M. J., & Lewis, J. S. (2010). Unconventional nuclides for radiopharmaceuti- cals. Mol Imaging, 9(1), 1-20.
- Holliger, P., & Hudson, P. J. (2005). Engineered anti- body fragments and the rise of single domains. Na- ture Biotechnology, 23(9), 1126-1136. doi:10.1038/ nbt1142
- Jauw, Y. W., Menke-van der Houven van Oordt, C. W., Hoekstra, O. S., Hendrikse, N. H., Vugts, D. J., Zijlstra, J. M., . . . van Dongen, G. A. (2016). Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clin- ical Trials? Front Pharmacol, 7, 131. doi:10.3389/ fphar.2016.00131
- Kaur, S., Venktaraman, G., Jain, M., Senapati, S., Garg, P. K., & Batra, S. K. (2012). Recent trends in an- tibody-based oncologic imaging. Cancer Lett, 315(2), 97-111. doi:10.1016/j.canlet.2011.10.017
- Kenanova, V., & Wu, A. M. (2006). Tailoring Anti- bodies for Radionuclide Delivery. Expert Opin- ion on Drug Delivery, 3(1), 53-70. doi:https://doi. org/10.1517/17425247.3.1.53
- Kikuchi, M., Clump, D. A., Srivastava, R. M., Sun, L., Zeng, D., Diaz-Perez, J. A., . . . Ferris, R. L. (2017). Preclinical immunoPET/CT imaging using Zr- 89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma. Onco- immunology, 6(7), e1329071. doi:10.1080/216240 2X.2017.1329071
- Knowles, S. M., & Wu, A. M. (2012). Advances in im- muno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol, 30(31), 3884-3892. doi:10.1200/JCO.2012.42.4887
- Kobayashi, H., Choyke, P. L., & Ogawa, M. (2016). Monoclonal antibody-based optical molecular im- aging probes; considerations and caveats in chem- istry, biology and pharmacology. Curr Opin Chem Biol, 33, 32-38. doi:10.1016/j.cbpa.2016.05.015
- Kumar, K., & Ghosh, A. (2021). Radiochemistry, Pro- duction Processes, Labeling Methods, and Immu- noPET Imaging Pharmaceuticals of Iodine-124. Molecules, 26(2). doi:10.3390/molecules26020414
- Kurihara, H., Hamada, A., Yoshida, M., Shimma, S., Hashimoto, J., Yonemori, K., . . . Tamura, K. (2015). (64)Cu-DOTA-trastuzumab PET imag- ing and HER2 specificity of brain metastases in HER2-positive breast cancer patients. EJNMMI Res, 5, 8. doi:10.1186/s13550-015-0082-6
- Lamberts, L. E., Menke-van der Houven van Oor- dt, C. W., ter Weele, E. J., Bensch, F., Smeenk, M. M., Voortman, J., . . . de Vries, E. G. (2016). ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer be- fore Anti-Mesothelin Antibody-Drug Conjugate Treatment. Clin Cancer Res, 22(7), 1642-1652. doi:10.1158/1078-0432.CCR-15-1272
- Liu, H., Moy, P., Kim, S., Xia, Y., Rajasekaran, A., Na- varro, V., . . . Bander, N. H. (1997). Monoclonal antibodies to the extracellular domain of pros- tate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res, 57(17), 3629-3634.
- Liu, H., Rajasekaran, A. K., Moy, P., Xia, Y., Kim, S., Navarro, V., . . . Bander, N. H. (1998). Consti- tutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res, 58(18), 4055-4060.
- Lövqvist, A., Humm, J., Sheikh, A., Finn, R., Koziorowski, J., Ruan, S., . . . Larson, S. M. (2001). PET Imaging of 86Y-Labeled Anti-Lewis Y Mono- clonal Antibodies in a Nude Mouse Model: Com- parison Between 86Y and 111In Radiolabels. J Nucl Med, 42, 1281-1287.
- Lu, R.-M., Hwang, Y.-C., Liu, I. J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020). Develop- ment of therapeutic antibodies for the treatment of diseases. Journal of Biomedical Science, 27(1), 1. doi:10.1186/s12929-019-0592-z
- Lubberink, M., & Herzog, H. (2011). Quantitative imaging of 124I and 86Y with PET. Eur J Nucl Med Mol Imaging, 38 Suppl 1(Suppl 1), S10-18. doi:10.1007/s00259-011-1768-2
- Maier, F. C., Wild, A. M., Kirchen, N., Holm, F., Fuchs, K., Schwenck, J., . . . Wiehr, S. (2019). Comparative immuno-Cerenkov luminescence and -PET imag- ing enables detection of PSMA(+) tumors in mice using (64)Cu-radiolabeled monoclonal antibod- ies. Appl Radiat Isot, 143, 149-155. doi:10.1016/j. apradiso.2018.09.006
- McKnight, B. N., & Viola-Villegas, N. T. (2018). (89) Zr-ImmunoPET companion diagnostics and their impact in clinical drug development. J Labelled Comp Radiopharm, 61(9), 727-738. doi:10.1002/ jlcr.3605
- Mikolajczak, R., van der Meulen, N. P., & Lapi, S. E. (2019). Radiometals for imaging and theranos- tics, current production, and future perspectives. J Labelled Comp Radiopharm, 62(10), 615-634. doi:10.1002/jlcr.3770
- Morais, M., & Ma, M. T. (2018). Site-specific chela- tor-antibody conjugation for PET and SPECT im- aging with radiometals. Drug Discov Today Tech- nol, 30, 91-104. doi:10.1016/j.ddtec.2018.10.002
- Nayak, T. K., Garmestani, K., Baidoo, K. E., Milenic, D. E., & Brechbiel, M. W. (2011). PET imaging of tumor angiogenesis in mice with VEGF-A-target- ed (86)Y-CHX-A’’-DTPA-bevacizumab. Int J Can- cer, 128(4), 920-926. doi:10.1002/ijc.25409
- Nayak, T. P., & Brechbiel, M. W. (2009). Radioimmu- noimaging with Longer-Lived Positron-Emitting Radionuclides: Potentials and Challenges. Biocon- jug Chem, 20, 825-841. doi:10.1021/bc800299f
- Nelson, A. L. (2010). Antibody fragments: hope and hype. MAbs, 2(1), 77-83. doi:10.4161/ mabs.2.1.10786
- O’Donoghue, J. A., Smith-Jones, P. M., Humm, J. L., Ruan, S., Pryma, D. A., Jungbluth, A. A., . . . Larson, S. M. (2011). 124I-huA33 antibody up- take is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET. J Nucl Med, 52(12), 1878-1885. doi:10.2967/jnumed.111.095596
- Olafsen, T., Gu, Z., Sherman, M. A., Leyton, J. V., Wit- kosky, M. E., Shively, J. E., . . . Reiter, R. E. (2007). Targeting, Imaging, and Therapy Using a Human- ized Antiprostate Stem Cell Antigen (PSCA) An- tibody. J Immunother, 30, 396-405.
- Palm, S., Enmon, R. M., Matei, C., Kolbert, K. S., Xu, S., Zanzonico, P. B., . . . Sgouros, G. (2003). Phar- macokinetics and Biodistribution of 86Y-Trastu- zumab for 90Y Dosimetry in an Ovarian Carcino- ma Model: Correlative MicroPET and MRI. J Nucl Med, 44, 1148-1155.
- Parakh, S., Lee, S. T., Gan, H. K., & Scott, A. M. (2022). Radiolabeled Antibodies for Cancer Imaging and Therapy. Cancers (Basel), 14(6). doi:10.3390/can- cers14061454
- Ping Li, W., Meyer, L. A., Capretto, D. A., Sherman, C. D., & Anderson, C. J. (2008). Receptor-bind- ing, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tu- mors. Cancer Biother Radiopharm, 23(2), 158-171. doi:10.1089/cbr.2007.0444
- Povoski, S. P., Hall, N. C., Murrey, D. A., Jr., Sharp, D. S., Hitchcock, C. L., Mojzisik, C. M., . . . Bahnson, R. R. (2013). Multimodal imaging and detection strategy with 124 I-labeled chimeric monoclo- nal antibody cG250 for accurate localization and confirmation of extent of disease during laparo- scopic and open surgical resection of clear cell renal cell carcinoma. Surg Innov, 20(1), 59-69. doi:10.1177/1553350612438416
- Ramogida, C. F., & Orvig, C. (2013). Tumour tar- geting with radiometals for diagnosis and thera- py. Chem Commun (Camb), 49(42), 4720-4739. doi:10.1039/c3cc41554f
- Reddy, S., & Robinson, M. K. (2010). Immuno-posi- tron emission tomography in cancer models. Se- min Nucl Med, 40(3), 182-189. doi:10.1053/j.sem- nuclmed.2009.12.004
- Saharma, S., Baldi, A., Singh, R. K., & Sharma, R. K. (2018). Regulatory Framework of Radiopharma- ceuticals: Current Status and Future Recommen- dations. Research Journal of Life Sciences, Bioin- formatics, Pharmaceutical and Chemical Sciences, 4(3). doi:10.26479/2018.0403.25
- Sarcan, E. T., & Özer, A. Y. (2021). Zirconium-89 ra- diopharmaceuticals: Current status and future. In A. Y. Özer (Ed.), New Trends in Radiopharmaceu- ticals. (pp. 16-22). Ankara: Türkiye Klinikleri.
- Sarcan, E. T., Silindir-Gunay, M., Ozer, A. Y., & Hart- man, N. (2021). 89Zr as a promising radionuclide and it’s applications for effective cancer imaging. Journal of Radioanalytical and Nuclear Chemistry, 330(1), 15-28. doi:10.1007/s10967-021-07928-0
- Schrama, D., Reisfeld, R. A., & Becker, J. C. (2006). Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov, 5(2), 147-159. doi:10.1038/ nrd1957
- Sihver, W., Pietzsch, J., Krause, M., Baumann, M., Steinbach, J., & Pietzsch, H. J. (2014). Radiola- beled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy. Pharmaceuticals (Basel), 7(3), 311-338. doi:10.3390/ph7030311
- Tamura, K., Kurihara, H., Yonemori, K., Tsuda, H., Suzuki, J., Kono, Y., . . . Fujiwara, Y. (2013). 64Cu-DOTA-Trastuzumab PET Imaging in Pa- tients with HER2-Positive Breast Cancer. Jour- nal of Nuclear Medicine, 54(11), 1869-1875. doi:10.2967/jnumed.112.118612
- Templar Smith, B. (2012). Polyclonal and Monoclonal Antibodies. In J. Norenbergh (Ed.), Introduction to Diagnostic and Therapeutic Monoclonal Anti- bodies (Vol. 17): University of New Mexico Health Science Center and Pharmacy Continuing Educa- tion.
- U.S.Pharmacopoeia. (2009). Radiopharmaceuti- cals for Positron Emission Tomography —Com- pounding. USP 32.
- Van Dongen, G. A., Huisman, M. C., Boellaard, R., Harry Hendrikse, N., Windhorst, A. D., Visser, G. W., . . . Vugts, D. J. (2015). 89Zr-immuno-PET for imaging of long circulating drugs and disease tar- gets: why, how and when to be applied? Q J Nucl Med Mol Imaging, 59(1), 18-38.
- van Dongen, G. A., Visser, G. W., Lub-de Hooge, M. N., de Vries, E. G., & Perk, L. R. (2007). Immu- no-PET: a navigator in monoclonal antibody de- velopment and applications. Oncologist, 12(12), 1379-1389. doi:10.1634/theoncologist.12-12-1379
- van Dongen, G. A., & Vosjan, M. J. (2010). Immu- no-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother Radio- pharm, 25(4), 375-385. doi:10.1089/cbr.2010.0812
- Verel, I., Visser, G. W., Boerman, O. C., van Eerd, J. E., Finn, R., Boellaard, R., . . . van Dongen, G. A. (2003). Long-lived positron emitters zirco- nium-89 and iodine-124 for scouting of ther- apeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm, 18(4), 655-661. doi:10.1089/108497803322287745
- Verel, I., Visser, G. W., Vosjan, M. J., Finn, R., Boel- laard, R., & van Dongen, G. A. (2004). High-qual- ity 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmu- notherapy. Eur J Nucl Med Mol Imaging, 31(12), 1645-1652. doi:10.1007/s00259-004-1632-8
- Vugts, D. J., Visser, G. W., & van Dongen, G. A. (2013). 89Zr-PET radiochemistry in the development and application of therapeutic monoclonal antibodies and other biologicals. Curr Top Med Chem, 13(4), 446-457. doi:10.2174/1568026611313040005
- Wadas, T. J., Wong, E. H., Weisman, G. R., & Ander- son, C. J. (2010). Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconi- um for PET and SPECT Imaging of Disease. Chem Rev, 110, 2858-2902.
- Wallberg, H., & Stahl, S. (2013). Design and eval- uation of radiolabeled tracers for tumor imag- ing. Biotechnol Appl Biochem, 60(4), 365-383. doi:10.1002/bab.1111
- WHO. (2017). The International Pharmacopoe- ia Radiopharmaceuticals: General Monograph. Retrieved from https://www.who.int/docs/de- fault-source/medicines/norms-and-standards/ current-projects/qas13-542rev2-general-chap- ter-radiopharmaceuticals.pdf?sfvrsn=516dbf81_2
- Wong, K. J., Baidoo, K. E., Nayak, T. K., Garmestani, K., Brechbiel, M. W., & Milenic, D. E. (2011). In vitro and in vivo pre-clinical analysis of a F(ab’)2 fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers. EJNMMI Research, 1(1), 1. doi:10.1186/2191-219X-1-1
- Wong, K. J., Baidoo, K. E., Nayak, T. K., Garmestani, K., Brechbiel, M. W., & Milenic, D. E. (2011). In vitro and in vivo pre-clinical analysis of a F(ab’)2 fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers. EJNMMI Res, 1.
- Xie, Q., Zhu, H., Wang, F., Meng, X., Ren, Q., Xia, C., & Yang, Z. (2017). Establishing Reliable Cu-64 Production Process: From Target Plating to Mo- lecular Specific Tumor Micro-PET Imaging. Mol- ecules, 22(4). doi:10.3390/molecules22040641
- Zaheer, J., Kim, H., Lee, Y. J., Lim, S. M., & Kim, J. S. (2019). Comparison between Fractionated Dose and Single Dose of Cu-64 Trastuzumab Therapy in the NCI-N87 Gastric Cancer Mouse Model. Int J Mol Sci, 20(19). doi:10.3390/ijms20194708
- Zeng, D., Guo, Y., White, A. G., Cai, Z., Modi, J., Fer- dani, R., & Anderson, C. J. (2014). Comparison of conjugation strategies of cross-bridged macrocy- clic chelators with cetuximab for copper-64 radio- labeling and PET imaging of EGFR in colorectal tumor-bearing mice. Mol Pharm, 11(11), 3980- 3987. doi:10.1021/mp500004m
| APA | SARCAN BOZKIR E, OZER A (2023). Monoclonal Antibodies and Immuno-PET Imaging: An Overview. , 165 - 182. 10.55262/fabadeczacilik.1172020 |
| Chicago | SARCAN BOZKIR ELIF TUGCE,OZER Asuman Yekta Monoclonal Antibodies and Immuno-PET Imaging: An Overview. (2023): 165 - 182. 10.55262/fabadeczacilik.1172020 |
| MLA | SARCAN BOZKIR ELIF TUGCE,OZER Asuman Yekta Monoclonal Antibodies and Immuno-PET Imaging: An Overview. , 2023, ss.165 - 182. 10.55262/fabadeczacilik.1172020 |
| AMA | SARCAN BOZKIR E,OZER A Monoclonal Antibodies and Immuno-PET Imaging: An Overview. . 2023; 165 - 182. 10.55262/fabadeczacilik.1172020 |
| Vancouver | SARCAN BOZKIR E,OZER A Monoclonal Antibodies and Immuno-PET Imaging: An Overview. . 2023; 165 - 182. 10.55262/fabadeczacilik.1172020 |
| IEEE | SARCAN BOZKIR E,OZER A "Monoclonal Antibodies and Immuno-PET Imaging: An Overview." , ss.165 - 182, 2023. 10.55262/fabadeczacilik.1172020 |
| ISNAD | SARCAN BOZKIR, ELIF TUGCE - OZER, Asuman Yekta. "Monoclonal Antibodies and Immuno-PET Imaging: An Overview". (2023), 165-182. https://doi.org/10.55262/fabadeczacilik.1172020 |
| APA | SARCAN BOZKIR E, OZER A (2023). Monoclonal Antibodies and Immuno-PET Imaging: An Overview. FABAD Journal of Pharmaceutical Sciences, 48(1), 165 - 182. 10.55262/fabadeczacilik.1172020 |
| Chicago | SARCAN BOZKIR ELIF TUGCE,OZER Asuman Yekta Monoclonal Antibodies and Immuno-PET Imaging: An Overview. FABAD Journal of Pharmaceutical Sciences 48, no.1 (2023): 165 - 182. 10.55262/fabadeczacilik.1172020 |
| MLA | SARCAN BOZKIR ELIF TUGCE,OZER Asuman Yekta Monoclonal Antibodies and Immuno-PET Imaging: An Overview. FABAD Journal of Pharmaceutical Sciences, vol.48, no.1, 2023, ss.165 - 182. 10.55262/fabadeczacilik.1172020 |
| AMA | SARCAN BOZKIR E,OZER A Monoclonal Antibodies and Immuno-PET Imaging: An Overview. FABAD Journal of Pharmaceutical Sciences. 2023; 48(1): 165 - 182. 10.55262/fabadeczacilik.1172020 |
| Vancouver | SARCAN BOZKIR E,OZER A Monoclonal Antibodies and Immuno-PET Imaging: An Overview. FABAD Journal of Pharmaceutical Sciences. 2023; 48(1): 165 - 182. 10.55262/fabadeczacilik.1172020 |
| IEEE | SARCAN BOZKIR E,OZER A "Monoclonal Antibodies and Immuno-PET Imaging: An Overview." FABAD Journal of Pharmaceutical Sciences, 48, ss.165 - 182, 2023. 10.55262/fabadeczacilik.1172020 |
| ISNAD | SARCAN BOZKIR, ELIF TUGCE - OZER, Asuman Yekta. "Monoclonal Antibodies and Immuno-PET Imaging: An Overview". FABAD Journal of Pharmaceutical Sciences 48/1 (2023), 165-182. https://doi.org/10.55262/fabadeczacilik.1172020 |
